FACILITIES

Qilu Pharmaceutical has eight manufacturing sites with facilities for chemical synthesis, finished product, genetic engineering and fermentation.

Qilu Pharmaceutical has several installations for the production of active ingredients which include fermentation, chemical synthesis, biochemistry, genetic engineering, chemical synthesis, lyophilization and sterile crystallization.

It also includes a structure for finished dosage forms including powder for injection, lyophilized powder for injection, small volume parenteral solutions, tablets, capsules, ointments, sprays and eye drops.

Fermentation

The annual fermentation capacity is over 34,000 tons. Facility approved by FDA (US Food and Drug Administration) and EDQM (European Directorate for the Quality of Medicines).

Sterile crystallization

Equipped with the latest technology, its production capacity exceeds 900 tons annually, mainly of active ingredient cephalosporin. Approved by TGA (Therapeutic Goods Admnistration of Australia).

Injectables

TGA (Therapeutic Goods Admnistration of Australia) and MCC (Medicine Control Council Africa) have approved 15 different production lines.

The annual production of lyophilized powder is 100 million vials, 700 million vials of powder for injection and 400 million of ampoules of small volume parenteral solutions.

Solid oral forms

With an annual production capacity of 3.5 billion tablets and capsules, for various oncological and central nervous system products, as well as cephalosporin. It is MCC (Medicine Control Council Africa) approved.

Genetic engineering

With a 2,5 km² surface area we have state of the art fermentation and purification equipment.

The annual output of recombinant proteins is 3,000 g and the main products are rhG-CSF and rhIL-11.

Chemical systhesis

Flexibility batch size varies widely from 39 g to 10,000 Kg. Facility approved by FDA(US Food and Drug Administration), EDQM (European Directorate for the Quality of Medicines), TGA (Therapeutic Goods Admnistration of Australia), KFDA (Korea Food and Drug Administration) and MHLW (Ministry of Health, Labour and Welfare Japan). Large capacity of over 2,000 tons per year.

Qilu Pharmaceutical is the biggest worldwide supplier for amikacin, tazobactam and oncology APIs. We are one of the biggest suppliers of cephalosporin APIs from 7-ACA in the world.

There are several product lines dedicated to the manufacture of penicillin, cephalosporin, and oncological products, as well as central nervous system, cardiovascular and cerebrovascular treatments.

Lyophillized sterile products

The annual production capacity is over 930 tons. Approved by FDA (US Food and Drug Administration), EDQM (European Directorate for the Quality of Medicines), TGA (Therapeutic Goods Admnistration of Australia) and KFDA (Korea Food and Drug Administration).

This facility is one of the first manufacturers in China to make lyophilized sterile products and has a highly-qualified team of professionals as well as lyophillization technology imported from Germany, Spain and France.